EMQN (European Molecular Genetics Quality Network)

Belkins
The EMQN is a not-for-profit organisation promoting quality in molecular genetic testing through the provision of external quality assessment (proficiency testing schemes) and the organisation of best practice meetings and publication of guidelines.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

MINDMED ANNOUNCES TRANSITIONS TO MANAGEMENT TEAM

Mind Medicine (MindMed) Inc. | December 30, 2021

news image

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

Read More

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

news image

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

news image

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

news image

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

news image

INDUSTRIAL IMPACT

MINDMED ANNOUNCES TRANSITIONS TO MANAGEMENT TEAM

Mind Medicine (MindMed) Inc. | December 30, 2021

Mind Medicine Inc. a leading biotech company developing psychedelic-inspired therapies, announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role. "On behalf of the Board of Directors and Executive team, I would like to thank Bradford for his contributions to the Company and wish him all the best in his future endeavors. We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under...

Read More
news image

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More
news image

DIVERSE BIOTECH ANNOUNCES ORPHAN-DRUG DESIGNATION FOR TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA

Diverse Biotech | May 04, 2020

Diverse Biotech, Inc. www.diversebiotech.com has announced the U.S. Food & Drug Administration (FDA) has granted an orphan-drug designation request for one of its investigational new therapies for treatment of newly diagnosed glioblastoma, in conjunction with standard treatment, following adjuvant combined chemo-radiation. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, (Orphan Drug Act) including tax credits for qualified clinical te...

Read More
news image

CELL AND GENE THERAPY

BRAZIL’S SENAI CIMATEC DOSES FIRST HEALTHY VOLUNTEERS IN PHASE 1 TRIAL OF HDT BIO’S RNA COVID-19 VACCINE

HDT Bio Corp. | January 17, 2022

HDT Bio Corp., a U.S. developer of immunotherapies for oncology and infectious diseases and SENAI CIMATEC, an important Brazilian education, research, and innovation institute, have dosed the first healthy volunteers in Brazil in a Phase 1 trial of HDT Bio’s RNA COVID-19 vaccine, HDT-301. SENAI CIMATEC will conduct the clinical trial under the name Vaccine RNA MCTI-CIMATEC-HDT. The vaccine uses HDT Bio’s proprietary lipid nanoparticle RNA-delivery technology. Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us